

1 **Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-**
2 **attenuated influenza vaccines in UK adolescents**

3
4 Cecilia Jay^{1*}, Emily Adland², Anna Csala², Nicholas Lim², Stephanie Longet³, Ane Ogbe¹, PITCH
5 Consortium, Jeremy Ratcliff¹, Oliver Sampson⁴, Craig P Thompson⁵, Lance Turtle⁶, Eleanor
6 Barnes^{1,7}, Susanna Dunachie^{1,7}, Paul Klenerman^{1,7}, Miles Carroll^{1,7}, Philip Goulder^{2*}

7
8 Affiliations:

9 ¹ Nuffield Department of Medicine, University of Oxford, Oxford, UK

10 ² Department of Paediatrics, University of Oxford, Oxford, UK

11 ³ Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

12 ⁴ Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK

13 ⁵ Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Warwick,
14 UK

15 ⁶ Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool,
16 UK

17 ⁷ NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust

18

19

20 * Correspondence:

21 Prof. Philip Goulder

22 philip.goulder@paediatrics.ox.ac.uk

23

24 Cecilia Jay

25 cecilia.jay@ndm.ox.ac.uk

26

27

28

29 Keywords: SARS-CoV-2, vaccine, COVID-19, adolescents, immunity

30 Abstract

31 Key to understanding COVID-19 correlates of protection is assessing vaccine-induced
32 immunity in different demographic groups. Sex- and age-specific immune differences have a
33 wide impact on outcomes from infections and immunisations. Typically, adult females make
34 stronger immune responses and have better disease outcomes but suffer more adverse
35 events following vaccination and are more prone to autoimmune disease. To understand
36 better the mechanisms underlying these differences in vaccine responses, we studied
37 immune responses to two doses of BNT162b2 Pfizer COVID-19 vaccine in an adolescent
38 cohort (n=34, ages 12-16), an age group previously shown to make significantly greater
39 immune responses to the same vaccine compared to young adults. At the same time, we
40 were able to evaluate immune responses to the co-administered live attenuated influenza
41 vaccine, which has been shown to induce stronger immune responses in adult females. Blood
42 samples from 34 adolescents taken pre- and post-vaccination with COVID-19 and influenza
43 vaccines were assayed for SARS-CoV-2-specific IgG and neutralising antibodies, and cellular
44 immunity specific for SARS-CoV-2 and endemic betacoronaviruses. IgG targeting influenza
45 lineages contained in the influenza vaccine was also assessed. As previously demonstrated,
46 total IgG responses to SARS-CoV-2 Spike antigens were significantly higher among vaccinated
47 adolescents compared to adults (aged 32-52) who received the BNT162b2 vaccine
48 (comparing infection-naïve, 49,696 vs 33,339; p=0.03; comparing SARS-CoV-2 previously-
49 infected, 743,691 vs 269,985; p<0.0001) by MSD v-plex assay. However, unexpectedly,
50 antibody responses to BNT162b2 and the live-attenuated influenza vaccine were not higher
51 among female adolescents compared to males; among infection-naïve adolescents, antibody
52 responses to BNT162b2 were higher in males than females (62,270 vs 36,951 p=0.008). No
53 sex difference was identified in vaccinated adults. These unexpected findings may result from
54 the introduction of novel mRNA vaccination platforms, generating patterns of immunity
55 divergent from established trends, and providing new insights into what might be protective
56 following COVID-19 vaccination.

57

58 Abstract length: 299

59 Word length: 4081

60 References: 51

61

62

63

64

65

66

67

68

69 Introduction

70 The BNT162b2 Pfizer-BioNTech COVID-19 vaccine was authorised for 12-15 year olds in June
71 2021 in the United Kingdom as a 30µg one-dose regimen by the Medicines and Healthcare
72 Products Regulatory Agency.[1] This was extended to a two-dose regimen in early 2022.[2] In
73 the United Kingdom, the first dose of BNT162b2 was administered in adolescents alongside
74 the AstraZeneca intranasal seasonal live-attenuated influenza vaccine (LAIV) FluenzTetra,
75 therefore presenting a unique opportunity to study vaccine-induced immunity in this age
76 group.

77

78 Older age is a primary risk factor for severe COVID-19, perhaps due to the reduced immune
79 capacity with age driven by persistent inflammation and cellular dysfunction.[3] The death
80 rate of COVID-19 is 0.66% overall, increasing to 7.8% in over 80s.[4] The majority of young
81 people experience mild COVID-19; severe disease and multisystem inflammatory syndrome
82 only occurs in a minority of paediatric patients.[5] Adolescents and children display rapid and
83 adaptable immune responses that may contribute to improved resolution of infections, such
84 as abundant IgM memory B-cells, broad and rapidly produced natural antibodies, and lower
85 inflammatory cytokine responses.[6,7] Differential COVID-19 outcomes between adults and
86 children may also be influenced by pre-existing immune responses to endemic coronaviruses
87 that might circulate at higher levels in children.[6] Notably, adolescents between 12 and 15
88 years of age generate 1.76-fold higher IgG responses to BNT162b2 than 16-25 year olds,
89 indicating either potential age-related changes in immune response even during
90 adolescence, or an increase in cross-reactivity with endemic coronaviruses that enhances
91 vaccine responsiveness and declines with age.[8] Finally, older individuals are more likely to
92 have immunodeficiencies or chronic diseases which increase their risk of severe COVID-19.

93

94 In addition to age, understanding the role of sex in vaccine response is crucial for developing
95 more effective vaccines. Adult females aged 18-49 have been shown to generate twofold
96 greater antibody responses to trivalent influenza vaccines,[9] and adult females are more at
97 risk for serious adverse events (SAEs) after vaccination, including after the ChAdOx1 Oxford-
98 AstraZeneca COVID-19 vaccine. [10–12] In one study, females given half-dose influenza
99 vaccine made marginally stronger antibody responses compared to age-matched males who
100 received full-dose vaccine.[9] Greater vaccine-induced immune responses in females could
101 potentially facilitate reduced dosing regimens for females, which may minimise incidence of
102 SAEs, improve vaccine uptake, and improve vaccine supply. However, young males
103 experience more vaccine-induced myocarditis after BNT162b2, suggesting that immune
104 responses to mRNA vaccines may be differentially influenced by sex.[13,14] Adolescents
105 undergoing puberty face significant changes in levels of sex hormones such as testosterone
106 and oestrogen, which are known to modulate immunity to SARS-CoV-2 and influenza.[15,16]

107

108 To explore sex- and age-specific differences in humoral and cellular immunity to BNT162b2,
109 we studied adolescent and adult cohorts in the United Kingdom who received this vaccine.
110 Data collected from adolescents in this study were compared to the Protective Immunity
111 from T-cells in Healthcare Workers (PITCH) cohort of vaccinated healthcare workers (HCWs)
112 aged 32-52, who received two doses of BNT162b2 and also represented a mixture of
113 previously-infected and infection-naïve individuals.[17] We explored age-specific effects on
114 immunity within the adolescent cohort as well as between adolescents and adults.

115 Furthermore, we examined whether sex-specific immune effects were evident. As not all

116 adolescents also received the LAIV, we were also able to assess whether co-administration of
117 LAIV appeared to influence the magnitude of response to BNT162b2. Furthermore, many
118 studies of adolescent responses to BNT162b2 have used prior SARS-CoV-2 infection as an
119 exclusion criterion[18,19]. Here, we enrolled both SARS-CoV-2 infection-naïve and previously-
120 infected adolescents to understand the role of prior or ongoing infection in vaccine response.
121

122 Results

123 Cohort description

124 In November and December of 2021, 34 adolescents aged between 12 and 16 were recruited
125 into the study through their enrolment at schools in Oxford, UK (Fig. 1A). All 34 individuals
126 received the BNT162b2 vaccine; 26 (76%) also received the LAIV on the same day as the first
127 dose of BNT162b2. 47% of individuals (n=16) were female, and the median age was 14.1
128 years (12.2-16) (Fig. 1B). 33 individuals were Caucasian, one individual was Asian. No
129 individuals were on any regular medication.

130

131 The adult cohort to which adolescent data was compared was the PITCH cohort of vaccinated
132 HCWs.[20,21] This cohort consisted of 589 adults aged 32-52 who had received two doses of
133 BNT162b2 28 days apart. Here, IgG data from 170 adults and neutralising antibody (nAb) data
134 from 10 adults was used to compare to data from adolescents.

135

136

137 Humoral immune responses to BNT162b2 vaccination

138 To evaluate the immunogenicity of the BNT162b2 vaccine among adolescents, we first
139 characterised humoral responses using MSD-platform immunoassays to measure
140 quantitatively the total immunoglobulin G (IgG) response to SARS-CoV-2 Spike (S), the
141 receptor-binding domain (RBD) of S, and SARS-CoV-2- N (Fig. 2A). Both infection-naïve and
142 previously-infected adolescents made significantly greater IgG responses to S post-V1 than
143 pre-V1 (61 vs 49,696, x803, p=0.0005 and 13,409 vs 788,568, x55, p<0.0001, respectively,
144 Wilcoxon signed-rank test) and greater anti-RBD IgG responses (263 vs 16,861, x64, p=0.0005
145 and 6,556 vs 351,068 x53, p<0.0001, respectively, Wilcoxon signed-rank test) (Fig. 2A). Anti-S
146 and RBD IgG responses increased post-V2 in all groups, but only anti-RBD IgG increased
147 significantly and only in previously-infected individuals (90,067 vs 318,687, x3.5, p=0.008,
148 Wilcoxon signed-rank test). Notably, two doses of BNT162b2 in infection-naïve individuals
149 gave similar levels of IgG to one dose of vaccine in previously-infected individuals.

150

151 Since nAbs as well as total IgG are reported to be a correlate of protective immunity against
152 symptomatic COVID-19,[22] we next assessed a surrogate of nAb activity using the MSD-
153 platform ACE2 inhibition assay,[23] which is well correlated with live virus neutralisation
154 assays.[20,21,24,25] In contrast to IgG responses, only previously-infected individuals
155 generated increased nAb responses following the first dose of vaccine (6 vs 149, x24,
156 p=0.0002, Wilcoxon signed-rank test) (Fig. 2B), and fold change in nAb response to S and RBD
157 was higher in previously-infected individuals post-V1 compared to infection-naïve individuals
158 (1.1 vs 28, p<0.0001 and 1.3 vs 23, p=0.0002, respectively, Mann-Whitney tests)
159 (Supplementary Fig. 1AB). After two doses of BNT162b2, infection-naïve individuals reached
160 similar nAb titres to previously-infected individuals after one dose, supporting the idea that
161 two doses of vaccine are required for a robust neutralising response in infection-naïve
162 individuals.

163

164 To determine how breadth of nAb response to SARS-CoV-2 variants is impacted by
165 vaccination and prior infection, the MSD-platform ACE2 inhibition assay was carried out
166 against the common variants of SARS-CoV-2 in both infection-naïve and previously-infected
167 individuals (Fig. 2C and Supp. Fig. 2). Notably, previously-infected individuals made broad nAb
168 responses against all studied variants following the first dose, whereas high-titre nAb

169 responses against these variants were only observed following the second dose in infection-
170 naive individuals.

171

172 **Cellular immune responses to BNT162b2 vaccination**

173 We next characterised the cellular immune response in adolescents following first and
174 second doses of BNT162b2. Proliferation assays measuring the dilution of CellTrace Violet
175 (CTV) stain (Thermo Fisher Scientific, USA) following stimulation of peripheral blood
176 mononuclear cells (PBMCs) with pools of SARS-CoV-2 peptides spanning the S1 and S2
177 regions of S, the membrane protein (M) and N, and the S2 region of endemic human
178 coronaviruses (HCoVs) HCoV-HKU1 and HCoV-OC43 were performed at pre-V1, post-V1, pre-
179 V2 and post-V2 timepoints (Fig. 3, Supp. Fig. 3, Supp. File 1). In contrast to humoral responses
180 to BNT162b2, SARS-CoV-2-specific CD4+ T-cell proliferative responses were similar in
181 infection-naïve compared to previously-infected individuals after a single dose of vaccine.
182 The T-cell response in previously-infected individuals increased following vaccination, but not
183 significantly, suggesting stable cellular immunity over time.

184

185 Although T-cell responses to HCoV-OC43 S2 and HCoV-HKU1 S2 were identified in several
186 individuals, particularly previously-infected individuals, there was no significant impact of
187 BNT162b2 vaccination on the magnitude of T-cell responses.

188

189

190

191 **Higher magnitude antibody responses to BNT162b2 in adolescents versus adults**

192 The role of age in immune response to vaccination was of particular interest in this study. To
193 determine whether the responses observed in adolescents to the BNT162b2 vaccine were
194 stronger than those observed in adults, as previously shown,[8] we compared the adolescent
195 data to humoral responses in adults (32-52 years) from the PITCH cohort 28 days after the
196 first dose of BNT162b2 (Fig. 4).[26,27] PITCH is a consortium of universities and UK Health
197 Security Agency (UK HSA) with the aim of characterising infection-acquired and vaccine-
198 induced immunity to SARS-CoV-2 in HCWs. Here, as reported for adolescents receiving two
199 vaccines,[18,19] post-V1, infection-naïve adolescents generated higher magnitude anti-S IgG
200 responses than infection-naïve adults (49,696 vs 33,339, x1.5, $p=0.03$, Mann-Whitney test)
201 and previously-infected adolescents generated greater anti-S IgG responses than previously-
202 infected adults (743,691 vs 269,985, x2.9, $p<0.0001$, Mann-Whitney test) (Fig. 4A). Post-V1
203 nAb responses did not differ significantly between adolescents and adults (Fig. 4B).

204

205 To investigate why infection-naïve adolescents generate relatively weak nAb responses post-
206 V1, despite a strong total IgG response, we sought to address the hypothesis that cross-
207 reactive antibody responses to endemic HCoVs might be present at higher levels in infection-
208 naïve adolescents, thereby interfering with the generation of novel SARS-CoV-2-specific
209 responses to BNT162b2, as has been suggested previously.[28,29] Humoral responses to
210 HCoVs have been associated with worse COVID-19 outcomes, through the inhibition of novel
211 responses to SARS-CoV-2 as a result of immune imprinting or 'original antigenic sin'. [28] Pre-
212 existing cross-reactive IgG may promote higher magnitude IgG responses to the conserved S2
213 region of SARS-CoV-2 S following vaccination, whilst it is the less conserved S1 region that is
214 the target of most neutralising antibodies.[30] Children have been reported to display higher

215 immunity to endemic HCoVs than adults,[31] perhaps due to high circulation of viruses in
216 schools.

217

218 Our data supported the hypothesis that cross-reactive antibody responses to HCoVs are
219 associated with weaker vaccine-induced neutralising responses: in this study, the ratio of IgG
220 targeting betacoronaviruses HCoV-HKU1 and HCoV-OC43 S to IgG targeting SARS-CoV-2 S
221 was significantly higher in infection-naïve adolescents versus infection-naïve adults (0.4 vs
222 0.06, x5.9, $p<0.0001$; 1.9 vs 0.2, x8.3, $p<0.0001$, Mann-Whitney tests) and versus previously-
223 infected adolescents (0.4 vs 0.04, x10, $p<0.0001$; 1.9 vs 0.3, x7.1, $p<0.0001$, Mann-Whitney
224 test) post-V1 (Fig. 4CD). Furthermore, the ratio of IgG targeting HCoV-HKU1 and HCoV-OC43
225 S to IgG targeting SARS-CoV-2 S was significantly negatively correlated with nAb response
226 (HKU1: $r=-0.75$, $p<0.0001$; OC43: $r=-0.84$, $p<0.0001$) in all adolescents, though this
227 significance was lost when adolescents were divided into infection-naïve and previously-
228 infected.

229

230 **Sex differences in response to BNT162b2 vaccination**

231 Females typically make stronger IgG responses than males following
232 vaccination,[10,11,32,33] including after influenza vaccines.[9,16] Surprisingly, therefore,
233 here, infection-naïve males generated significantly higher post-V1 IgG targeting both SARS-
234 CoV-2 S and RBD than females (62,270 vs 36,951, x2, $p=0.008$; 23,860 vs 11,443, x2, $p=0.02$,
235 respectively, Mann-Whitney tests) (Fig. 5AB). There was no significant difference in IgG
236 response between the sexes in previously-infected individuals (Fig. 5CD). Furthermore, there
237 was a trend towards a stronger RBD and S nAb response post-V1 in infection-naïve males
238 compared to infection-naïve females, although this was not significant ($p=0.07$ and $p=0.15$,
239 respectively, Mann-Whitney tests) (Fig. 5EF). There was no significant difference in baseline
240 IgG responses between males and females. There was no sex difference in the humoral
241 response to BNT162b2 in adults.[26]

242

243 A potential mediator of immune sex differences is the effect of sex hormones. Males enter
244 puberty on average 2 years later than females. To ensure males in this cohort had entered
245 puberty, steroid hormones including testosterone, dihydrotestosterone (DHT) and
246 progesterone were measured by Tandem mass spectrometry; these data are the focus of a
247 future publication. All but the two youngest males (12 years 2 months and 12 years 10
248 months) demonstrated pubertal androgen levels. Testosterone correlated with age in males
249 only ($r=0.47$, $p=0.05$).

250

251 **Humoral responses to LAIV administration**

252 As well as the immune response to BNT162b2, co-administration of the LAIV enabled the
253 characterisation of immunity against influenza following vaccination. To determine the effect
254 of the LAIV on lineage-specific anti-haemagglutinin (HA) IgG titres, enzyme-linked
255 immunosorbent assays (ELISAs) were performed on pre- and post-LAIV samples for the 26
256 individuals who received the LAIV (Fig. 6). As expected, IgG titres were significantly higher
257 post-LAIV for A/Cambodia (H3N2), A/Victoria (H1N1), and B/Phuket (Yamagata) (9.3 vs 13.9,
258 x1.5, $p<0.0001$; 11 vs 13.4, x1.2, $p=0.0002$; 7 vs 10.2, x1.5, $p<0.0001$; respectively, Wilcoxon
259 signed-rank tests) (Fig. 6A). Surprisingly, post-LAIV anti-HA IgG responses towards the
260 B/Washington (Victoria) lineage were not significantly increased compared to pre-LAIV. A
261 possible explanation lies in the observation that responses to B/Washington (Victoria) were

262 strongly correlated with age for both pre- and post-vaccine timepoints ($r=0.61$, $p=0.0001$,
263 $r=0.57$, $p=0.0008$, respectively, Spearman rank test) (Fig. 6BC). By contrast, there was no
264 correlation between age and post-LAIV IgG for A/Cambodia (H3N2) or B/Phuket (Yamagata),
265 and for A/Victoria (H1N1) pre-LAIV IgG levels only were weakly correlated with age ($r=0.39$,
266 $p=0.02$, Spearman rank test). This pattern suggests that natural exposure to B/Washington
267 (Victoria) is so frequent in this cohort that vaccination against this strain of influenza does not
268 add significantly to the natural immunity that is accumulated over adolescence. Pre-existing
269 immunity to influenza has been widely described, from prior infection and vaccination, in
270 support of this finding. [34,35]

271

272 Unexpectedly, and in contrast to previous studies,[36] adolescents previously-infected with
273 SARS-CoV-2 who received both BNT162b2 and the LAIV generated significantly higher post-
274 V1 IgG targeting both S and RBD compared to adolescents previously-infected with SARS-
275 CoV-2 who received BNT162b2 alone (286,185 vs 817,284, $x2.8$, $p=0.01$; 159,101 vs 379,429,
276 $x2.3$, $p=0.01$, Mann-Whitney tests), although this analysis involved very small numbers of
277 individuals (Fig. 6DE). We did not find a sex difference in the IgG response to the LAIV (Fig 6F-
278 I).

279

280 Discussion

281 Understanding the quantitative markers of vaccine immunogenicity, as well as confounding
282 patient demographic factors, will help better define correlates of protection against SARS-
283 CoV-2 and improve interpretability of future vaccine trials. Due to the discrepancy between
284 IgG and nAb response in infection-naive adolescents, these data support the use of nAb titre
285 as well as total IgG when assessing vaccine immunogenicity.[37,38] Other studies have
286 established that BNT162b2 and the CoronaVac inactivated virus vaccine elicit robust nAb
287 responses post-V2 in infection-naive adolescents.[19,39] The totality of data described herein
288 suggest that a robust nAb response is prompted in infection-naive adolescents after two
289 doses but previously-infected adolescents only require one dose. Previous studies in adults
290 have differed in their evaluation of vaccine-induced versus infection-induced humoral
291 immunity, but these data show that a similar IgG response is elicited in adolescents after
292 natural infection and one vaccine dose compared to two vaccine doses only.[40] The
293 longevity of these responses is uncertain due to the lack of an extended follow up in this
294 cohort but should be the focus of future studies.

295

296 Other research has shown that two doses of BNT162b2 elicit robust T_H1 T-cell responses in
297 adults, with widespread interferon-gamma (IFN γ) production.[26,41] S-specific T-cell
298 responses following vaccination with BNT162b2 were generated post-V2, but not post-V1, in
299 another cohort of infection-naive adolescents.[18] This contrasts with the data described
300 herein, where one dose of BNT162b2 is sufficient to induce a significant increase in S-specific
301 CD4+ T-cells in infection-naive adolescents. The lack of a significant reduction in T-cell
302 response across timepoints suggests that these responses are stable over several months, as
303 reported elsewhere.[42,43] Similarly to the IgG response, SARS-CoV-2-specific T-cell
304 responses post-V1 in previously-infected individuals reach similar frequencies to post-V2 in
305 infection-naive individuals.

306

307 BNT162b2 has been shown to promote greater IgG production in adolescents compared to
308 adults post-V1.[18] Similarly, here, both infection-naive and previously-infected adolescents

309 generated stronger IgG responses than adults. This may result from higher exposure to
310 endemic HCoVs in adolescents, promoting a stronger IgG response to conserved SARS-CoV-2
311 antigens. However, only previously-infected adolescents generated a strong and broad nAb
312 response targeting multiple variants, and infection-naïve adolescents appeared to rely more
313 on cross-reactive antibodies following their first dose of BNT162b2 compared to both
314 infection-naïve adults and previously-infected adolescents. One interpretation for these
315 patterns is immune imprinting, wherein prior exposure to circulating endemic coronaviruses
316 negatively impacts vaccine-induced immunity. Higher levels of cross-reactive IgG have been
317 described in children compared to adults,[31,44,45] and this may result in a stronger
318 memory B-cell response that is weakly neutralising following the first dose of BNT162b2 in
319 infection-naïve adolescents. In previously-infected adolescents, prior exposure to SARS-CoV-2
320 may overcome immune imprinting and enable a robust nAb response. This is supported by
321 the strong negative correlation between HCoV:SARS-CoV-2 IgG ratio and nAb response.

322
323 Immune responses to many adult and childhood vaccines, as well as responses to natural
324 infection with viral pathogens, are consistently higher in females and associated with
325 increased inflammation and autoimmunity as well as CD4+-skewed T-cell responses and
326 greater B cell activation and IgG production. [10,11,32,33] Female IgG responses to influenza
327 vaccines have been shown to reach twice the magnitude of male IgG responses, and females
328 also report more frequent SAEs to viral vaccines.[11,33] One exception to this trend is COVID-
329 19 mRNA vaccines, for which vaccine-induced myocarditis is more frequent in young males.
330 [13,14,46] Notably, in this cohort, we observe increased post-V1 anti-S and anti-RBD IgG
331 responses in infection-naïve males compared to infection-naïve females, in contrast to
332 expectations based on other vaccines such as inactivated influenza vaccines.[9,11] We did
333 not observe a significant sex difference in anti-HA IgG titres following the LAIV - this is
334 surprising in the context of established literature,[10,11] but may be obscured by the very
335 small increase in anti-HA IgG post-V1 in this cohort, the effect of a live-attenuated rather
336 than inactivated influenza vaccine, the use of different serological assays, or the result of co-
337 administration with BNT162b2.[47] Furthermore, there was no sex difference in anti-SARS-
338 CoV-2 IgG for either infection-naïve or previously-infected adults from the PITCH dataset.

339
340 A potential confounder for this study is that adolescents of this age group are likely at
341 different stages of puberty and therefore have diverse levels of testosterone, oestrogen and
342 progesterone. Furthermore, males experience puberty at older ages compared to females,
343 and therefore the sex difference identified herein may result from the confounding effects of
344 puberty. If many male adolescents had not gone through puberty at the time of sampling, the
345 increased humoral responses to vaccination in males may result from an absence of the
346 immunosuppressive effects of androgens. Steroid hormones were measured in this cohort,
347 and although these results are the focus of a future publication, it was identified that all but
348 two males had pubertal levels of testosterone. This promotes confidence in the results of
349 comparisons between sexes, as the majority of males had undergone puberty at time of
350 sampling.

351
352 Finally, the correlation between B/Washington influenza IgG responses with age in 12–16-
353 year-olds, as well as the lack of anti-B/Washington HA IgG boosting following the LAIV,
354 suggests recent exposure to the B/Washington strain of influenza in this cohort. Our findings
355 that co-administration of BNT162b2 with the LAIV improves IgG response in previously-

356 infected individuals is in contrast with findings for NVX-COV2373, where co-administration
357 with inactivated quadrivalent influenza vaccines reduced SARS-CoV-2-specific IgG titres[36].
358 However, studies of co-administration of COVID-19 mRNA vaccines with quadrivalent
359 influenza vaccines in adults have reported no reduction in antibody response compared to
360 administration of mRNA vaccines alone.[48,49] A potential explanation for improved anti-S
361 IgG responses following co-administration may be increased innate immune activation due to
362 intranasal LAIV administration, particularly in the nasal mucosa, leading to greater SARS-CoV-
363 2-specific local T-helper cell activation.

364

365 This study has some limitations. The small numbers of adolescents assayed in this cohort
366 make broad conclusions difficult, particularly when making comparisons between small sub-
367 groups such as co-administered LAIV/BNT162b2 and BNT162b2-alone individuals. No
368 mucosal samples were taken and so mucosal immunity is not assessed in this cohort.
369 Neutralisation responses to SARS-CoV-2 were estimated using the MSD-ACE2 inhibition
370 assay. This has shown to correlate with live virus assays,[20,21,24] but live virus
371 neutralisation is likely a more accurate measure of nAbs. In addition, no neutralisation assays
372 were carried out for influenza lineages, which would have shed further light on the
373 functionality of humoral immunity to influenza. Furthermore, the lack of an extended follow-
374 up in this study makes assessments of immune durability impossible but should be the focus
375 of future studies.

376

377 Taken together, these data paint a complex picture of vaccine-induced immunity in
378 adolescents, with a potential role for immune sex and age differences in determining
379 antibody responses to vaccination. These findings have important implications for paediatric
380 vaccination regimes, such as the potential benefit of co-administration with influenza
381 vaccines, and the necessity to consider sex and age when studying vaccine-induced
382 immunity.

383

384 **Materials and Methods**

385

386 **Ethics**

387 This longitudinal cohort study was conducted from November 2021 to February 2022. Eligible
388 participants were healthy adolescents aged 12-16 who either had no history of SARS-
389 CoV-2 infection or had experienced mild disease prior to enrolment. Eligible participants
390 were identified via their participation in school-based vaccination events. Written informed
391 consent was obtained from all patients and ethical approval was given by the Central
392 University Research Ethics Committee (reference: CUREC R71346/RE001). 32-52-year-old
393 healthy HCWs were recruited as part of the PITCH consortium of HCWs under the GI Biobank
394 Study 16/YH/0247, approved by the research ethics committee (REC) at Yorkshire & The
395 Humber - Sheffield Research Ethics Committee on 29 July 2016, which has been amended for
396 this purpose on 8 June 2020.

397

398 **Sample collection and processing**

399 For the BNT162b2 vaccination (dose 1 (V1) and dose 2 (V2)), patients received 30 µg of
400 vaccine intramuscularly. LAIV was administered immediately after V1 only; patients received
401 0.1mL intranasally in both nostrils. Whole blood samples from all 34 individuals were taken
402 immediately before V1 (sample pre-V1). Samples from all 34 individuals were taken a mean
403 of 37 days after V1 (33-39]) (sample post-V1), from 23 individuals 2 days before V2 (0-8) and
404 96 days after V1 (81-114) (sample pre-V2), and from 14 individuals 35 days after V2 (30-40)
405 (sample post-V2). All whole blood samples were processed the same day as collection as
406 described in the methods. All serum samples were tested for anti-Spike (S) and anti-
407 nucleocapsid (N) IgG; individuals were classified as seropositive if their anti-N IgG titre was
408 above the previously determined MSD immunoassay cut-off at any point in the study or if
409 their anti-spike (S) IgG titre was above the cut-off pre-V1[26]. The percentage of seropositive
410 patients increased from 52% to 71% over the course of the study.

411

412 Whole blood samples were transported from their collection site to an academic laboratory
413 and processed the same day. PBMCs and plasma were isolated as described elsewhere[51].
414 Briefly, PBMCs were isolated using Lymphoprep (1.077 g/ml, Stem Cell Technologies) through
415 density gradient centrifugation. Plasma and PBMCs were collected and plasma was spun at
416 2000g for 10 minutes to remove platelets. PBMCs were washed twice with RPMI 1640
417 (Sigma, USA) containing 10% heat inactivated foetal calf serum, 2mM L-Glutamine and 1mM
418 penicillin/streptomycin (Sigma). An estimated ten million cells were resuspended in media
419 and counted using a Muse Cell Analyser (Luminex Corporation, USA). Plasma and PBMCs
420 were frozen and stored at -80°C for later use. Steroid hormone concentrations were
421 quantified by tandem mass spectrometry by collaborators at Imperial College London.

422

423 **MSD serological assays**

424 IgG responses to SARS-CoV-2 S, N and RBD as well as the S proteins of HCoV-OC43, HCoV-
425 NL63, HCoV-229E, HCoV-HKU1, SARS-CoV-1 and MERS-CoV were measured using a Meso
426 Scale Diagnostics (MSD) V-plex immunoassay 'Coronavirus panel 3' (MSD, USA) according to
427 the manufacturer's protocol. Plates were incubated in Blocker A solution for 30 minutes at
428 room temperature (RT) with shaking at 700rpm. Plasma or serum was diluted at 1:1000 and
429 1:10000 in Diluent 100, and a seven-point standard curve of MSD reference standard
430 beginning at 1:10 was prepared in duplicate. Three internal controls and an in-house control

431 of convalescent serum were also used, with Diluent 100 used as a blank. Plates were washed
432 three times with MSD Wash Buffer and samples and standards added to the plate before
433 incubation at RT for two hours with shaking at 700rpm. Plates were washed three times with
434 MSD Wash Buffer and detection antibody solution was added. Plates were incubated for one
435 hour at RT with shaking at 700rpm. Plates were washed three times with MSD Wash Buffer.
436 Neat MSD Gold Read Buffer was added, and plates were read immediately on a MESO
437 QuickPlex SQ 120 (MSD, USA). Data was analysed using MSD Discovery Workbench software.
438 Thresholds for seropositivity were taken from analyses of pre-pandemic sera, as published
439 elsewhere[26], and defined as 1160 AU/ml for SARS-CoV-2 S, 1169 for RBD, and 3874 for N.
440

441 nAb titres were quantified using Meso Scale Diagnostics ACE2 inhibition assays, 'Panel 27',
442 (analytes: SARS-CoV-2 S, SARS-CoV-2 S (B.1.351), SARS-CoV-2 S (B.1.617.2; AY.4), SARS-CoV-2
443 S (BA.2), SARS-CoV-2 S (BA.2.12.1), SARS-CoV-2 S (BA.2+L452M), SARS-CoV-2 S (BA.2+L452R),
444 SARS-CoV-2 S (BA.3), SARS-CoV-2 S (BA.4), SARS-CoV-2 S (BA.5)) according to the
445 manufacturer's instructions. Plates were incubated in Blocker A solution for 30 minutes at RT
446 with shaking at 700rpm. Serum was diluted at 1:10 and 1:100, and a seven-point standard
447 curve of MSD calibration reagent was prepared with 4-fold serial dilutions. Plates were
448 washed three times with MSD Wash Buffer and samples and calibrator were added to the
449 plate. Plates were incubated at RT for one hour with shaking at 700rpm. Sulfo tagged ACE2
450 protein was added to the plate and incubated at RT for one hour with shaking at 700rpm.
451 Plates were washed three times with MSD Wash Buffer and MSD Gold Read Buffer was
452 added. Plates were read immediately on a MESO QuickPlex SQ 120 (MSD, USA). Data was
453 analysed using MSD Discovery Workbench software.
454

455 **Influenza ELISA assay**

456 IgG responses to influenza A/Victoria (H1N1), B/Washington (Victoria), A/Cambodia (H3N2),
457 and B/Phuket (Yamagata) HA antigens were measured using an indirect ELISA. HA antigens
458 (The Native Antigen Company, Oxford) were diluted to 1µg/ml in PBS and used to coat 535
459 Nunc-Immuno 96-well plates (Thermo Fisher Scientific, USA) overnight at 4°C
460 (A/Victoria/2570/2019 (H1N1)pdm09-like virus (NCBI Accession Number: EPI1799581),
461 amino acids 1-528 and C-terminal His-tag; Cambodia/e0826360/2020 (H3N2)-like virus (NCBI
462 Accession Number: EPI1799580), amino acids 46-469 and C-terminal His-tag;
463 B/Washington/02/2019 (B/Victoria lineage)-like virus (NCBI Accession Number: EPI1846769),
464 amino acids 31-469 and C-terminal His-tag, B/Phuket/3073/2013 (B/Yamagata Lineage)-Like
465 virus] (NCBI Accession Number: EPI1799823), amino acids 44-466 and C-terminal His-tag)
466 Plates were washed three times in 0.1% PBS-Tween, before blocking with Casein-PBS Buffer
467 for one hour at RT. Plasma was diluted 1:200 in Casein-PBS Buffer and added to plates in
468 duplicate. A ten-point standard curve of pooled highly reactive sera beginning at 1:25 was
469 prepared in duplicate and added to plates. Casein-PBS Buffer was used as a negative control.
470 Plates were incubated for two hours at RT and washed six times in 0.1% PBS-Tween.
471 Secondary antibody – goat anti-human IgG conjugated to alkaline phosphatase (Sigma, USA)
472 was diluted 1:1000 in Casein-PBS Buffer and added to plates. Plates were incubated for one
473 hour at RT before washing six times in 0.1% PBS-Tween. 4-nitrophenyl phosphate in
474 diethanolamine buffer (Pierce, Loughborough, UK) was added as a substrate and plates were
475 incubated for 15 minutes. 405nm absorbance was read using an ELx800 microplate reader
476 (Cole Parmer, London, UK).
477

478
479

480 **Proliferation assay**

481 T-cell responses were assayed using a CellTrace Violet Proliferation assay as described
482 elsewhere[51]. Cryopreserved PBMCs were thawed in 30mL RPMI containing 10% human AB
483 serum (Sigma), 2mM L-Glut and 1mM Pen-Strep. Cells were washed twice with PBS and
484 stained with CellTrace Violet (Life Technologies) at 2.5uM for 10 minutes at RT. Cold FCS was
485 added to quench the reaction. Cells were plated at 250,000 cells per well in a 96-well round-
486 bottom plate. Peptide pools covering SARS-CoV-2 S1, S2, M and N, as well as HCoV-OC43 and
487 HCoV-HKU1 S, were added to stimulate cells at a final concentration of 1ug/ml (Mimotopes,
488 USA) (Supplementary File 1). Media containing 0.1% DMSO (Sigma) was used as a negative
489 control. Phytohaemagglutinin L (Sigma) was used as a positive control at a final concentration
490 of 2 ug/ml. Plates were incubated at 37°C, 5% CO₂, 95% humidity for 7 days, with a
491 hemimedia change at day 4. On day 7, cells were washed in PBS and stained with
492 fluorochrome-conjugated antibodies for CD4, CD8, and CD3 in PBS. LIVE/DEAD Fixable Aqua
493 was used as a viability marker (Thermo Fisher). Cells were fixed in 4% paraformaldehyde
494 (Sigma) for ten minutes at 4°C and washed in PBS before storing at 4°C in the dark before
495 being run on an MACSquant X (Miltenyi). Gating strategy can be viewed in Supp. Fig. 8.

496

497 **Statistical analysis**

498 All analyses were performed in GraphPad Prism 9.0. For pairwise comparisons, two-tailed
499 Mann-Whitney tests were used for unpaired data and Wilcoxon signed-rank tests for paired
500 data. For correlations, Spearman rank tests were used.

501

502 **Contributions**

503 **CJ**: Conceptualisation, Formal analysis, Investigation, Writing – Original Draft Preparation,
504 Review & Editing, Visualisation **EA**: Investigation, Data Curation, Writing – Review & Editing,
505 Project administration **AC**: Investigation, Data Curation, Writing – Review & Editing, Project
506 administration **NL**: Investigation, Writing – Review & Editing **SL**: Formal analysis,
507 Investigation, Writing – Review & Editing **AO**: Investigation, Writing – Review & Editing **JR**:
508 Writing - Review & Editing **OS**: Investigation, Writing – Review & Editing **PITCH Consortium**:
509 Investigation, Formal analysis, Data Curation **CT**: Resources, Writing – Review & Editing,
510 Methodology **EB**: Conceptualization, Writing – Review & Editing, **SD**: Supervision, Writing –
511 Review & Editing **LT**: Supervision **PK**: Supervision, Writing – Review & Editing,
512 Conceptualization, Methodology **MC**: Supervision, Writing – Review & Editing, Methodology
513 **PG**: Conceptualization, Methodology, Resources, Writing – Review & Editing, Supervision,
514 Project administration, Funding acquisition

515

516 **Funding**

517 P.K. is funded by WT109965MA and is an NIHR Senior Investigator. S.J.D. is funded by an
518 NIHR Global Research Professorship (NIHR300791). E.B. Is funded by an NIHR Senior
519 Investigator award; the views expressed do not represent those of the NIHR or the NHS. The
520 PITCH consortium was funded by the UK Department of Health and Social Care and UKRI
521 (MR/W02067X/1), with contributions from UKRI/NIHR through the UK Coronavirus
522 Immunology Consortium (MR/V028448/1), the Huo Family Foundation and The National
523 Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant
524 Reference Number COV19-RECPLAS).

525

526 **Acknowledgements**

527 We are grateful to staff at the schools from which the participants were enrolled and to the
528 participants and their families.

529

530 The authors declare no competing interests.

531

532 References

- 533 1. The MHRA concludes positive safety profile for Pfizer/BioNTech vaccine in 12- to 15-
534 year-olds. In: GOV.UK [Internet]. [cited 21 Oct 2022]. Available:
535 [https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile-](https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile-for-pfizerbiontech-vaccine-in-12-to-15-year-olds)
536 [for-pfizerbiontech-vaccine-in-12-to-15-year-olds](https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile-for-pfizerbiontech-vaccine-in-12-to-15-year-olds)
- 537 2. COVID-19 vaccination: a guide to a second dose for young people aged 16 to 17. In:
538 GOV.UK [Internet]. [cited 21 Oct 2022]. Available:
539 [https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-](https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-children-and-young-people/covid-19-vaccination-a-guide-to-a-second-dose-for-young-people-aged-16-to-17)
540 [children-and-young-people/covid-19-vaccination-a-guide-to-a-second-dose-for-young-](https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-children-and-young-people/covid-19-vaccination-a-guide-to-a-second-dose-for-young-people-aged-16-to-17)
541 [people-aged-16-to-17](https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-children-and-young-people/covid-19-vaccination-a-guide-to-a-second-dose-for-young-people-aged-16-to-17)
- 542 3. Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2,
543 COVID-19 and the aging immune system. *Nat Aging*. 2021;1: 769–782.
544 doi:10.1038/s43587-021-00114-7
- 545 4. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
546 severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious*
547 *Diseases*. 2020;20: 669–677. doi:10.1016/S1473-3099(20)30243-7
- 548 5. Kabeerdoss J, Pilia RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19,
549 multisystem inflammatory syndrome in children, and Kawasaki disease: immunological
550 mechanisms, clinical manifestations and management. *Rheumatol Int*. 2021;41: 19–32.
551 doi:10.1007/s00296-020-04749-4
- 552 6. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the
553 proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2
554 infections. *Arch Dis Child*. 2021;106: 429–439. doi:10.1136/archdischild-2020-320338
- 555 7. Carsetti R, Quintarelli C, Quinti I, Mortari EP, Zumla A, Ippolito G, et al. The immune
556 system of children: the key to understanding SARS-CoV-2 susceptibility? *The Lancet*
557 *Child & Adolescent Health*. 2020;4: 414–416. doi:10.1016/S2352-4642(20)30135-8
- 558 8. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety,
559 Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *New*
560 *England Journal of Medicine*. 2021;385: 239–250. doi:10.1056/NEJMoa2107456
- 561 9. Engler RJM, Nelson MR, Klote MM, VanRaden MJ, Huang C-Y, Cox NJ, et al. Half- vs Full-
562 Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects
563 on Immune Responses. *Archives of Internal Medicine*. 2008;168: 2405–2414.
564 doi:10.1001/archinternmed.2008.513
- 565 10. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes
566 of Vaccination over the Life Course. *Annu Rev Cell Dev Biol*. 2017;33: 577–599.
567 doi:10.1146/annurev-cellbio-100616-060718
- 568 11. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16:
569 626–638. doi:10.1038/nri.2016.90

- 570 12. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety
571 and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a
572 preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*.
573 2020;396: 467–478. doi:10.1016/S0140-6736(20)31604-4
- 574 13. Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. *Circulation*.
575 2021;144: 471–484. doi:10.1161/CIRCULATIONAHA.121.056135
- 576 14. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. Symptomatic
577 Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination.
578 *Pediatrics*. 2021;148: e2021052478. doi:10.1542/peds.2021-052478
- 579 15. Li F, Boon ACM, Michelson AP, Foraker RE, Zhan M, Payne PRO. Estrogen hormone is an
580 essential sex factor inhibiting inflammation and immune response in COVID-19. *Sci*
581 *Rep*. 2022;12: 9462. doi:10.1038/s41598-022-13585-4
- 582 16. Furman D, Hejblum BP, Simon N, Jovic V, Dekker CL, Thiébaud R, et al. Systems analysis of
583 sex differences reveals an immunosuppressive role for testosterone in the response to
584 influenza vaccination. *PNAS*. 2014;111: 869–874. doi:10.1073/pnas.1321060111
- 585 17. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody
586 responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve
587 UK health-care workers: a multicentre prospective cohort study. *The Lancet Microbe*.
588 2022;3: e21–e31. doi:10.1016/S2666-5247(21)00275-5
- 589 18. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al. Immunogenicity
590 and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy
591 adolescents. *Nat Commun*. 2022;13: 3700. doi:10.1038/s41467-022-31485-z
- 592 19. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety,
593 Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *New*
594 *England Journal of Medicine*. 2021;385: 239–250. doi:10.1056/NEJMoa2107456
- 595 20. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody
596 responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve
597 UK health-care workers: a multicentre prospective cohort study. *The Lancet Microbe*.
598 2022;3: e21–e31. doi:10.1016/S2666-5247(21)00275-5
- 599 21. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity
600 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*. 2021;184:
601 5699-5714.e11. doi:10.1016/j.cell.2021.10.011
- 602 22. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
603 against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27:
604 2032–2040. doi:10.1038/s41591-021-01540-1
- 605 23. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA
606 vaccine candidate for COVID-19. *Nat Commun*. 2020;11: 2601. doi:10.1038/s41467-
607 020-16505-0


- 608 24. Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, et al. Two doses
609 of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2
610 variants of concern. *Nat Commun.* 2021;12: 5061. doi:10.1038/s41467-021-25167-5
- 611 25. Grunau B, Prusinkiewicz M, Asamoah-Boaheng M, Golding L, Lavoie PM, Petric M, et al.
612 Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies
613 and ACE-2 Inhibition among Vaccinated Individuals. Tripp RA, editor. *Microbiol Spectr.*
614 2022;10: e01315-22. doi:10.1128/spectrum.01315-22
- 615 26. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity
616 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell.* 2021;184:
617 5699-5714.e11. doi:10.1016/j.cell.2021.10.011
- 618 27. Angyal A, Longet S, Moore S, Payne RP, Harding A, Tipton T, et al. T-Cell and Antibody
619 Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and
620 Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational
621 Cohort Study. Rochester, NY: Social Science Research Network; 2021 Mar. Report No.:
622 ID 3812375. doi:10.2139/ssrn.3812375
- 623 28. McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, et al. Fatal COVID-
624 19 outcomes are associated with an antibody response targeting epitopes shared with
625 endemic coronaviruses. *JCI Insight.* 2022;7: e156372. doi:10.1172/jci.insight.156372
- 626 29. Beretta A, Cranage M, Zipeto D. Is Cross-Reactive Immunity Triggering COVID-19
627 Immunopathogenesis? *Front Immunol.* 2020;11. doi:10.3389/fimmu.2020.567710
- 628 30. Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan Y-H, et al. Structural
629 definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. *Commun*
630 *Biol.* 2022;5: 1–13. doi:10.1038/s42003-022-03262-7
- 631 31. Murray SM, Ansari AM, Frater J, Klenerman P, Dunachie S, Barnes E, et al. The impact of
632 pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.
633 *Nat Rev Immunol.* 2022; 1–13. doi:10.1038/s41577-022-00809-x
- 634 32. Furman D, Hejblum BP, Simon N, Jovic V, Dekker CL, Thiébaud R, et al. Systems analysis of
635 sex differences reveals an immunosuppressive role for testosterone in the response to
636 influenza vaccination. *Proceedings of the National Academy of Sciences.* 2014;111:
637 869–874. doi:10.1073/pnas.1321060111
- 638 33. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-
639 induced humoral immunity. *Semin Immunopathol.* 2019;41: 239–249.
640 doi:10.1007/s00281-018-0726-5
- 641 34. Wheatley AK, Kent SJ. Prospects for antibody-based universal influenza vaccines in the
642 context of widespread pre-existing immunity. *Expert Review of Vaccines.* 2015;14:
643 1227–1239. doi:10.1586/14760584.2015.1068125
- 644 35. Wild K, Smits M, Killmer S, Strohmeier S, Neumann-Haefelin C, Bengsch B, et al. Pre-
645 existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and

- 646 IgG response following seasonal influenza vaccination. *Nat Commun.* 2021;12: 6720.
647 doi:10.1038/s41467-021-27064-3
- 648 36. Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, et al. Safety,
649 immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered
650 with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-
651 blinded, placebo-controlled, phase 3 trial. *The Lancet Respiratory Medicine.* 2022;10:
652 167–179. doi:10.1016/S2213-2600(21)00409-4
- 653 37. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
654 antibody levels are highly predictive of immune protection from symptomatic SARS-
655 CoV-2 infection. *Nat Med.* 2021;27: 1205–1211. doi:10.1038/s41591-021-01377-8
- 656 38. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
657 Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine.*
658 2021;39: 4423–4428. doi:10.1016/j.vaccine.2021.05.063
- 659 39. Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity
660 of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents:
661 a double-blind, randomised, controlled, phase 1/2 clinical trial. *The Lancet Infectious*
662 *Diseases.* 2021;21: 1645–1653. doi:10.1016/S1473-3099(21)00319-4
- 663 40. Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection
664 with or vaccination against SARS-CoV-2 lead to lasting immunity? *The Lancet*
665 *Respiratory Medicine.* 2021;9: 1450–1466. doi:10.1016/S2213-2600(21)00407-0
- 666 41. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2
667 vaccine induces neutralizing antibodies and poly-specific T cells in humans. *Nature.*
668 2021; 1–10. doi:10.1038/s41586-021-03653-6
- 669 42. Guerrera G, Picozza M, D’Orso S, Placido R, Pirronello M, Verdiani A, et al. BNT162b2
670 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory
671 phenotype. *Science Immunology.* 2021;6: eabl5344. doi:10.1126/sciimmunol.abl5344
- 672 43. Moore SC, Kronsteiner B, Longet S, Adele S, Deeks AS, Liu C, et al. Evolution of long-term
673 vaccine-induced and hybrid immunity in healthcare workers after different COVID-19
674 vaccine regimens. *Med.* 2023;4: 191-215.e9. doi:10.1016/j.medj.2023.02.004
- 675 44. Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, Bradley T. Cross-reactive
676 antibody immunity against SARS-CoV-2 in children and adults. *Cell Mol Immunol.*
677 2021;18: 1826–1828. doi:10.1038/s41423-021-00700-0
- 678 45. Children develop robust and sustained cross-reactive spike-specific immune responses
679 to SARS-CoV-2 infection | *Nature Immunology.* [cited 15 Feb 2023]. Available:
680 <https://www.nature.com/articles/s41590-021-01089-8>
- 681 46. Snapiri O, Rosenberg Danziger C, Shirman N, Weissbach A, Lowenthal A, Ayalon I, et al.
682 Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19
683 Vaccine. *Pediatr Infect Dis J.* 2021;40: e360–e363. doi:10.1097/INF.0000000000003235

- 684 47. Sparks R, Lau WW, Liu C, Han KL, Vrindten KL, Sun G, et al. Influenza vaccination reveals
685 sex dimorphic imprints of prior mild COVID-19. *Nature*. 2023; 1–3.
686 doi:10.1038/s41586-022-05670-5
- 687 48. Hall KT, Stone VE, Ojikutu B. Reactogenicity and Concomitant Administration of the
688 COVID-19 Booster and Influenza Vaccine. *JAMA Network Open*. 2022;5: e2222246.
689 doi:10.1001/jamanetworkopen.2022.22246
- 690 49. Izikson R, Brune D, Bolduc J-S, Bourron P, Fournier M, Moore TM, et al. Safety and
691 immunogenicity of a high-dose quadrivalent influenza vaccine administered
692 concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged
693 >65 years: a phase 2, randomised, open-label study. *The Lancet Respiratory Medicine*.
694 2022;10: 392–402. doi:10.1016/S2213-2600(21)00557-9
- 695 50. Negriff S, Susman EJ. Pubertal Timing, Depression, and Externalizing Problems: A
696 Framework, Review, and Examination of Gender Differences. *Journal of Research on
697 Adolescence*. 2011;21: 717–746. doi:10.1111/j.1532-7795.2010.00708.x
- 698 51. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays
699 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral
700 responses. *Nat Commun*. 2021;12: 2055. doi:10.1038/s41467-021-21856-3


701

702 **Figure 1: Characteristics of the study cohort.** 34 adolescents were enrolled and provided
 703 consent, of which 18 were seropositive for S or N pre-V1. Samples were taken pre-V1 on the
 704 day of vaccination, a mean of 37 days post-V1, mean 2 days pre-V2, and mean 35 days post-
 705 V2 (A). The median age was 13 years 1 month for females (orange) and 14 years and 5
 706 months for males (blue) (B).



707
708


709 **Figure 2: Humoral responses following first and second doses of BNT162b2 in previously-**
 710 **infected and infection-naïve adolescents.**
 711 Anti-S, RBD and N IgG in infection-naïve (grey) and previously-infected (red) adolescents (A).
 712 Thresholds for IgG positivity were taken from previous literature.[26] nAbs targeting S in
 713 infection-naïve (grey) and previously-infected (red) adolescents using MSD ACE2-Spike
 714 binding inhibition assays (B). Percent inhibition of SARS-CoV-2 S-ACE2 binding as measured
 715 by MSD ACE2 inhibition assay in infection-naïve (grey) and previously-infected (red)
 716 adolescents targeting common SARS-CoV-2 lineages: Wuhan, B.1.351 (Beta), B.1.617.2/AY.4
 717 (Delta), BA.4 and BA.5 (Omicron) (C). P-values from Wilcoxon signed-rank tests. Fold change
 718 refers to the difference in total group medians.



719
720


721 **Figure 3: T-cell responses to SARS-CoV-2 S are boosted post-V1 and post-V2**

722 CellTrace Violet stains were used to assess proliferating CD4+ and CD8+ T-cells targeting the
 723 S1 region of S (A), the S2 region of S (B), M (C) and N (D) in infection-naïve (grey) and
 724 previously-infected (red) individuals (A). Data shows proliferating cells as a percentage of
 725 parent populations with DMSO background values subtracted. Thresholds for positivity were
 726 set at 1 as determined by previous literature.⁴⁹ P-values from Wilcoxon signed-rank tests.
 727 Fold change refers to the difference in total group medians. Values below 1% were given
 728 nominal values of 0.9%.




729
730

731 **Figure 4: Age-specific effects in the humoral response to BNT162b2**
 732 IgG targeting S in infection-naïve adolescents (grey circles), infection-naïve adults (32-52
 733 years) (grey squares), previously-infected adolescents (red circles) and previously-infected
 734 adults (red squares), pre-V1 (unfilled shapes) and post-V1 (filled shapes) as measured by an
 735 MSD v-plex immunoassay (A). nAb concentration targeting S in infection-naïve and
 736 previously-infected adolescents and adults as measured by an MSD ACE2-Spike binding
 737 immunoassay (B). The ratio of IgG targeting HCoV-OC43 S to SARS-CoV-2 S (C) and the ratio
 738 of IgG targeting HCoV-HKU1 S to SARS-CoV-2 S (D) in infection-naïve adolescents (grey
 739 circles), infection-naïve adults (grey squares), previously-infected adolescents (red circles),
 740 and previously-infected adults (red squares). P-values represent Mann-Whitney test values
 741 for unpaired data, and Wilcoxon signed-rank test values for paired data. Fold change
 742 calculated as the ratio of population medians.




743
 744
 745

746 **Figure 5: Infection-naïve males generate greater post-V1 IgG responses than females**
 747 IgG targeting S (A) and RBD (B) in infection-naïve adolescents pre-V1 (unfilled circles) and
 748 post-V1 (filled circles) in females (orange circles) and males (blue circles) as measured by an
 749 MSD v-plex immunoassay. IgG targeting S (C) and RBD (D) in previously-infected adolescents
 750 pre-V1 and post-V1 in females and males. Concentration of nAbs targeting S (E) and RBD (F)
 751 in infection-naïve adolescents as measured by an MSD ACE2-Spike binding inhibition assay.
 752 Concentration of nAbs targeting S (G) and RBD (H) in previously-infected adolescents. P-
 753 values represent Wilcoxon test values for paired data and Mann-Whitney test values for
 754 unpaired data. Fold change calculated as the ratio of population medians.



755
756

757 **Figure 6: Age- and sex-specific immunity to influenza following LAIV administration**
 758 IgG targeting haemagglutinin (HA) pre- (unfilled circles) and post- (filled circles) LAIV
 759 administration for the four influenza lineages (A) (P-values from Wilcoxon tests). The
 760 correlation between age and IgG targeting HA for the B/Washington lineage pre-LAIV (B) and
 761 post-LAIV (C) (Spearman rank r - and p -values). IgG targeting SARS-CoV-2 S (D) and RBD (E) in
 762 infection-naïve (grey) and previously-infected (red) adolescents who received the BNT162b2
 763 vaccine alone (BNT), or co-administered with the LAIV (LAIV + BNT) (Mann-Whitney p -values).
 764 IgG targeting HA pre- (unfilled circles) and post- (filled circles) LAIV administration in males
 765 (blue) and females (orange) for the four influenza lineages (F-I) (Wilcoxon p -values).



766
767